Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed

Key Inclusion Criteria: * Currently receiving an ARV regimen of DTG+F/TAF or DTG+F/TDF for the following minimum time periods: * ≥ 6 months (if there is documented or suspected nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) resistance prior to the screening visit) * ≥ 3 months (if there is no documented or suspected NRTI resistance prior to the screening visit) * Documented plasma HIV-1 ribonucleic acid (RNA) \< 50 copies/mL during treatment with DTG+F/TAF or DTG+F/TDF (for a minimum period of ≥ 6 or ≥ 3 months, as applicable) preceding the screening visit * Plasma HIV-1 RNA levels \< 50 copies/mL at screening visit * Estimated Glomerular Filtration Rate (eGFR) ≥ 30 mL/min according to the Cockcroft-Gault formula for creatinine clearance * No documented resistance to integrase stand transfer inhibitors (INSTIs) or confirmed virologic failure * Eligible adults with chronic hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection are permitted to enroll NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.